ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Thailand Moves to Regulate Gold Trading to Curb Baht Strength and Support Economic Growth 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Copper Prices Hit Record Highs as Metals Rally Gains Momentum on Geopolitical Tensions 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
South Korea Industry Minister Heads to Washington Amid U.S. Tariff Hike Concerns 
Dollar Struggles as Policy Uncertainty Weighs on Markets Despite Official Support 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Bank of Canada Holds Interest Rate at 2.25% Amid Trade and Global Uncertainty 
Celltrion announced that its COVID-19 test kit called DiaTrust has been given conditional approval by South Korea’s drug safety board. The biopharmaceutical company headquartered in Incheon shared the news on Monday, April 3.
The new coronavirus test kit
The Korea Herald reported that DiaTrust was jointly developed by Celltrion and Humasis, an R&D company based in S. Korea as well. The two sides made this antigen test kit that is said to be capable of detecting the newest COVID-19 variants that originated in Brazil and the U.K.
The rapid test kit can show results in as short as 15 minutes. It will identify the particular antigens of coronavirus that are present in the specimen collected from a person through a sterile nasal swab. Celltrion explained that what sets this kit apart from the other of its kind is that it uses a dual antigen method that can spot both N and S antigens.
“Celltrion will speed up its supply of COVID-19 test kit in the domestic market,” a company official stated. “The firm will submit additional clinical data concerning the test kit to the Ministry of Food and Drug Safety within three months.”
The biopharma company is expecting a surge in global demand for the DiaTrust COVID-19 test kit in the near future. In fact, in the U.S., the kit already received emergency use approval from the Food and Drug Administration (FDA). In April, the agency gave its authorization based on the clinical trial results that Celltrion submitted, and it is now reviewing additional clinical data.
Self-test kit to be marketed after gaining FDA nod
Celltrion was granted conditional approval for DiaTrust last week and to get its formal authorization from S. Korea’s Ministry of Food and Drug Safety. It needs to submit more clinical data within three months, as per the Korea Bio Medical Review.
It was added that the company is planning to supply the COVID-19 test kits via its subsidiary firm, Celltrion Pharm. It is also looking at other distribution outlets such as iMarket Korea.
Meanwhile, Celltrion’s new DiaTrust COVID-19 Ag home test kit was said to have shown results with high accuracy. However, it pointed out that suspected coronavirus patients with an obvious epidemiological connection to infection should get PCR tests at authorized screening centers set up by health authorities because the kits are just a supportive tool.
